Q-omics provides the consensus-scored HOXB13 profile across patient tissues and cancer cell-line models. HOXB13 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HOXB13 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, HOXB13 RNA expression shows 11,209 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where HOXB13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXB13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXB13 survival associations across molecular data types. HOXB13 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXB13 RNA expression–survival associations across cancer types. High HOXB13 expression shows unfavorable associations in KIRC, MESO, ACC, LGG, LIHC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HOXB13 RNA expression.
This table summarizes HOXB13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for HOXB13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXB13 shows higher tumor expression in KIRP, BRCA, STAD, HNSC, KIRC and UCEC. The KIRP box plot shows higher HOXB13 RNA expression in tumor versus normal tissue (log2 FC = +1.342, t-test p < 0.001).
This table shows molecular features associated with HOXB13 in patient tissues and cancer cell lines. In patient samples, HOXB13 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXB13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
